Protocol Ledger

NCT06115512 · Phase III · TERMINATED

A Phase 3 Study of AGA111 in Patients With Degenerative Disc Disease Undergoing Lumbar Interbody Fusion

Interventional Phase III clinical trial protocol NCT06115512 sponsored by Angitia Biopharmaceuticals in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-12-08 Enrollment: 412 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT06115512
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)412 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06115512
Protocol FieldVerified Registry Value
NCT IdentifierNCT06115512
Consolidated Lead SponsorAngitia Biopharmaceuticals
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusTERMINATED
Registered Enrollment412 participants (ACTUAL)
Registered Start Date2023-12-08
WhyStopped ClassificationSafety / Toxicity / Adverse Events

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI